secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001193125-24-133209
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies reports Q1 net loss $27.3M; cash runway only through Dec 2024, substantial doubt
--------------------------------------------------------------------------------

- Cash & equivalents $101.5M as of March 31, down from $141.4M at Dec 31, 2023.
- Net loss of $27.3M ($0.28 per share) vs $20.6M loss in Q1 2023, driven by R&D spending on VITESSE.
- Operating cash burn $34.7M in Q1 2024; company warns cash insufficient for 12 months, requires additional capital.
- VITESSE Phase 3 enrollment on track to screen last patient by Q3 2024; 86 sites in US, Canada, Europe, UK, Australia.
- Appointed Robert Pietrusko as Chief Regulatory Officer; he led over 35 BLA/NDA/MAA approvals globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312524133209/0001193125-24-133209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312524133209/d833388d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-133209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer